Our latest articles
EHA 2023 – Astrazeneca keeps up its complement defence
With Novartis’s oral contender looming, Astra talks up the importance of terminal complement inhibition.
Delays fail to Quell Treg interest
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Asco 2023 movers – maintaining the momentum
Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.
Aerow hits the mark for 4D Molecular
An early success with its cystic fibrosis gene therapy brings the company up.
Asco 2023 – Novocure sinks as Lunar’s limitations become clear
A pivotal lung cancer hit in an outdated setting means the company might struggle with adoption.
Asco 2023 – early first-line lung cancer data mined for datopotamab gold
The search is on for signals in front-line use, where Daiichi Sankyo and Astrazeneca have already bet big with the Trop2-targeted project.
Asco 2023 – Dizal heralds a “super-Tagrisso”
China’s Dizal, an unexpected targeted therapy star of Asco 2021, is back with even more impressive data.
Setrusumab’s second attempt shows promise
Ultragenyx and Mereo celebrate a mid-stage biomarker win, but have much to do in phase 3.
Asco 2023 – Enhertu hits with pan approach
Strong data prompt talk of a tumour-agnostic approval, but regulators could prove reluctant in the broad Her2 setting.
Asco 2023 – Bicara eyes head and neck niche
Impressive data in HPV-negative disease, potentially beating Keytruda, has the private group making pivotal plans.